KELOWNA, BRITISH COLUMBIA -- (MARKET WIRE) -- February 05, 2007 -- Sernova Corp. (TSX VENTURE: SVA), is pleased to announce its preliminary, preclinical animal studies have demonstrated long term survival and functioning of Sertolin, the Company’s patented insulin producing cellular replacement therapy. The findings will be presented at the upcoming Canadian Society of Transplantation Annual General Meeting March 16, 2007.
